Characteristics of the study participants
| Characteristic . | Patients . | Nonparticipants . | P . |
|---|---|---|---|
| N | 1089 | 792 | |
| Sex, n (%) | .003 | ||
| Female | 489 (44.9) | 298 (37.6) | |
| Male | 600 (55.1) | 494 (62.4) | |
| Race/ethnicity, no. (%) | |||
| White | 879 (80.7) | 554 (69.9) | .001 |
| Hispanic | 135 (12.4) | 128 (16.2) | |
| Other | 75 (6.9) | 110 (13.9) | |
| Institution, no. (%) | |||
| COH | 523 (48.0) | 362 (45.7) | .45 |
| UMN | 566 (52.0) | 430 (54.3) | |
| Mean age at transplantation, y (SD) | 30.8 (16.7) | 24.9 (15.7) | < .001 |
| Mean age at interview, y (SD) | 39.3 (15.4) | 34.8 (14.7) | < .001 |
| Mean time since transplantation, y (SD) | 8.6 (5.1) | 9.9 (5.5) | < .001 |
| Diagnosis, no. (%) | .001 | ||
| Acute leukemia | 357 (32.8) | 283 (35.7) | |
| Lymphoma | 331 (30.4) | 190 (24.0) | |
| Chronic leukemia | 204 (18.7) | 135 (17.0) | |
| Aplastic anemia | 64 (5.9) | 83 (10.5) | |
| Metabolic disease | 38 (3.5) | 44 (5.6) | |
| Immune disorder | 28 (2.6) | 14 (1.8) | |
| Breast cancer | 8 (0.7) | 15 (1.9) | |
| Sarcoma | 8 (0.7) | 0 (0.0) | |
| Other | 49 (4.5) | 28 (3.5) | |
| Stem-cell source, no. (%) | .01 | ||
| Bone marrow | 745 (68.4) | 615 (77.7) | |
| Peripheral-blood stem cells | 324 (29.8) | 165 (20.8) | |
| Cord blood | 20 (1.8) | 12 (1.5) | |
| Donor type, no. (%) | .006 | ||
| Autologous | 499 (45.8) | 268 (33.8) | |
| Allogeneic | 590 (54.2) | 524 (66.2) | |
| Conditioning regimen, no. (%) | .22 | ||
| Chemotherapy | 285 (26.2) | 210 (26.5) | |
| TBI and chemotherapy | 804 (73.8) | 582 (73.5) | |
| Chronic GVHD, allogeneic transplants only, no. (%) | .48 | ||
| Yes | 241 (40.8) | 214 (40.8) | |
| No | 349 (59.2) | 310 (59.2) |
| Characteristic . | Patients . | Nonparticipants . | P . |
|---|---|---|---|
| N | 1089 | 792 | |
| Sex, n (%) | .003 | ||
| Female | 489 (44.9) | 298 (37.6) | |
| Male | 600 (55.1) | 494 (62.4) | |
| Race/ethnicity, no. (%) | |||
| White | 879 (80.7) | 554 (69.9) | .001 |
| Hispanic | 135 (12.4) | 128 (16.2) | |
| Other | 75 (6.9) | 110 (13.9) | |
| Institution, no. (%) | |||
| COH | 523 (48.0) | 362 (45.7) | .45 |
| UMN | 566 (52.0) | 430 (54.3) | |
| Mean age at transplantation, y (SD) | 30.8 (16.7) | 24.9 (15.7) | < .001 |
| Mean age at interview, y (SD) | 39.3 (15.4) | 34.8 (14.7) | < .001 |
| Mean time since transplantation, y (SD) | 8.6 (5.1) | 9.9 (5.5) | < .001 |
| Diagnosis, no. (%) | .001 | ||
| Acute leukemia | 357 (32.8) | 283 (35.7) | |
| Lymphoma | 331 (30.4) | 190 (24.0) | |
| Chronic leukemia | 204 (18.7) | 135 (17.0) | |
| Aplastic anemia | 64 (5.9) | 83 (10.5) | |
| Metabolic disease | 38 (3.5) | 44 (5.6) | |
| Immune disorder | 28 (2.6) | 14 (1.8) | |
| Breast cancer | 8 (0.7) | 15 (1.9) | |
| Sarcoma | 8 (0.7) | 0 (0.0) | |
| Other | 49 (4.5) | 28 (3.5) | |
| Stem-cell source, no. (%) | .01 | ||
| Bone marrow | 745 (68.4) | 615 (77.7) | |
| Peripheral-blood stem cells | 324 (29.8) | 165 (20.8) | |
| Cord blood | 20 (1.8) | 12 (1.5) | |
| Donor type, no. (%) | .006 | ||
| Autologous | 499 (45.8) | 268 (33.8) | |
| Allogeneic | 590 (54.2) | 524 (66.2) | |
| Conditioning regimen, no. (%) | .22 | ||
| Chemotherapy | 285 (26.2) | 210 (26.5) | |
| TBI and chemotherapy | 804 (73.8) | 582 (73.5) | |
| Chronic GVHD, allogeneic transplants only, no. (%) | .48 | ||
| Yes | 241 (40.8) | 214 (40.8) | |
| No | 349 (59.2) | 310 (59.2) |
SD indicates standard deviation; TBI, total body irradiation; and GVHD, graft-versus-host disease.
P values are for comparison with patients nonparticipants.